サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1311092

血漿誘導体の世界市場規模調査＆予測：タイプ別、用途別、エンドユーザー別、地域別分析、2023-2030年

Global Blood Plasma Derivatives Market Size study & Forecast, by Type, by Application, by End User and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
血漿誘導体の世界市場規模調査＆予測：タイプ別、用途別、エンドユーザー別、地域別分析、2023-2030年
出版日: 2023年07月11日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血漿誘導体市場は、2022年に約 436億5,090万米ドルと評価され、予測期間2023-2030年には9.4%以上の健全な成長率で成長すると予測されています。

血漿誘導体市場とは、ヒト血漿から誘導される治療用製品の収集、加工、商品化を行う製薬産業の一分野を指します。これらの誘導体は、分画、精製、滅菌を含む複雑な製造工程を経て、血漿中に含まれる特定のタンパク質、抗体、その他の生理活性物質を分離・抽出して得られます。これらの製品は、免疫疾患、凝固障害、特定の遺伝性疾患の治療など、さまざまな治療目的に使用されます。血漿中誘導体市場は、感染症に罹患しやすい高齢者人口の増加や慢性疾患の蔓延といった要因によって牽引されています。

血漿誘導体は様々な病状の治療において重要な役割を果たしており、免疫不全、凝固障害、その他の疾患の患者に治療オプションを提供しています。国際糖尿病連合（IDF）によると、糖尿病は2021年に世界で5億3,700万人の成人を苦しめる可能性があり、10人に1人がその他の糖尿病を経験しています。さらに、老年人口や肥満人口は慢性疾患にかかりやすいです。世界銀行グループによると、世界の高齢者人口は2020年には7億2,700万人であり、今後30年間で3倍に増加し、2050年には15億人に達すると予測されています。したがって、慢性疾患の有病率の増加と高齢化人口の増加が市場の成長を促進しています。加えて、希少疾患に対する認識と診断の高まり、血漿誘導体の技術的進歩があります。しかし、厳しい規制が2023-2030年の予測期間を通じて市場の成長を阻害する可能性があります。

血漿誘導体の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、病院、クリニック、診断センターなどのヘルスケアインフラが発達しているため、2022年の市場を独占しました。これらの施設は、血漿の採取、処理、誘導体の製造に高度な能力を有しており、血漿ベースの製品の堅調な市場につながっています。また北米は、血漿由来製品に対する高い需要と償還制度により、予測期間中に最も急成長する地域と考えられています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における業界の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

  • 市場スナップショット
  • 世界市場・セグメント別市場推計・予測、2020-2030年
    • 血漿誘導体市場：地域別、2020-2030年
    • 血漿誘導体市場：タイプ別、2020-2030年
    • 血漿誘導体市場：用途別、2020-2030年
    • 血漿誘導体市場：エンドユーザー別、2020-2030年
  • 主要動向
  • 調査手法
  • 調査想定

第2章 血漿誘導体の世界市場定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界の血漿誘導体市場力学

  • 血漿誘導体市場のインパクト分析（2020-2030年）
    • 市場促進要因
      • 慢性疾患の増加
      • 老年人口の増加
    • 市場の課題
      • 厳しい規制
    • 市場機会
      • 希少疾患に対する認識と診断の高まり
      • 血漿誘導体の技術的進歩

第4章 世界の血漿誘導体市場：産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 血漿誘導体の世界市場：タイプ別

  • 市場スナップショット
  • 血漿誘導体の世界市場：タイプ別、実績-潜在能力分析
  • 血漿誘導体の世界市場：タイプ別、推定・予測2020-2030年
  • 血漿誘導体市場、サブセグメント別分析
    • アルブミン
    • 第VIII因子
    • 第IX因子
    • 免疫グロブリン
    • 高免疫グロブリン
    • その他

第6章 血漿誘導体の世界市場：用途別

  • 市場スナップショット
  • 血漿誘導体の世界市場、用途別、実績-潜在能力分析
  • 血漿誘導体の世界市場：用途別、推定・予測2020-2030年
  • 血漿誘導体市場、サブセグメント別分析
    • 血友病
    • 低ガンマグロブリン血症
    • 免疫不全症
    • フォンウィルブランド病
    • その他の用途

第7章 血漿誘導体の世界市場：エンドユーザー別

  • 市場スナップショット
  • 血漿誘導体の世界市場：エンドユーザー別、実績-潜在能力分析
  • 血漿誘導体の世界市場：エンドユーザー別、推定・予測2020-2030年
  • 血漿誘導体市場、サブセグメント分析
    • 病院
    • 診療所
    • その他エンドユーザー

第8章 血漿誘導体の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 血漿誘導体市場、地域別市場スナップショット
  • 北米の血漿誘導体市場
    • 米国
      • タイプ別推定・予測、2020-2030年
      • 用途別推定・予測、2020-2030年
      • エンドユーザーの推定・予測、2020-2030年
    • カナダ血漿誘導体市場
  • 欧州血漿誘導体市場スナップショット
    • 英国の血漿誘導体市場
    • ドイツの血漿誘導体市場
    • フランス血漿誘導体市場
    • スペイン血漿誘導体市場
    • イタリアの血漿誘導体市場
    • その他欧州血漿誘導体市場
  • アジア太平洋血漿誘導体市場スナップショット
    • 中国血漿誘導体市場
    • インド血漿誘導体市場
    • 日本の血漿誘導体市場
    • オーストラリア血漿誘導体市場
    • 韓国血漿誘導体市場
    • その他アジア太平洋地域血漿誘導体市場
  • ラテンアメリカ血漿誘導体市場スナップショット
    • ブラジルの血漿誘導体市場
    • メキシコ血漿誘導体市場
  • 中東・アフリカ血漿誘導体市場
    • サウジアラビア血漿誘導体市場
    • 南アフリカ血漿誘導体市場
    • その他中東とアフリカ血漿誘導体市場

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Baxter International Inc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Bayer AG
    • CSL Limited
    • Fusion Health Care Pvt. Ltd.
    • Grifols S.A.
    • Kedrion S.p.A.
    • LFB S.A.
    • Octapharma AG
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提
図表

LIST OF TABLES

  • TABLE 1. Global Blood Plasma DerivativesMarket, report scope
  • TABLE 2. Global Blood Plasma DerivativesMarket estimates & forecasts by Region 2020-2030 (USD Million)
  • TABLE 3. Global Blood Plasma DerivativesMarket estimates & forecasts by Type 2020-2030 (USD Million)
  • TABLE 4. Global Blood Plasma DerivativesMarket estimates & forecasts by Application 2020-2030 (USD Million)
  • TABLE 5. Global Blood Plasma DerivativesMarket estimates & forecasts by End User 2020-2030 (USD Million)
  • TABLE 6. Global Blood Plasma DerivativesMarket by segment, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 7. Global Blood Plasma DerivativesMarket by region, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 8. Global Blood Plasma DerivativesMarket by segment, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 9. Global Blood Plasma DerivativesMarket by region, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 10. Global Blood Plasma DerivativesMarket by segment, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 11. Global Blood Plasma DerivativesMarket by region, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 12. Global Blood Plasma DerivativesMarket by segment, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 13. Global Blood Plasma DerivativesMarket by region, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 14. Global Blood Plasma DerivativesMarket by segment, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 15. Global Blood Plasma DerivativesMarket by region, estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 16. U.S. Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 17. U.S. Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 18. U.S. Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 19. Canada Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 20. Canada Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 21. Canada Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 22. UK Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 23. UK Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 24. UK Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 25. Germany Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 26. Germany Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 27. Germany Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 28. France Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 29. France Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 30. France Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 31. Italy Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 32. Italy Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 33. Italy Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 34. Spain Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 35. Spain Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 36. Spain Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 37. RoE Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 38. RoE Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 39. RoE Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 40. China Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 41. China Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 42. China Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 43. India Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 44. India Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 45. India Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 46. Japan Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 47. Japan Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 48. Japan Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 49. South Korea Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 50. South Korea Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 51. South Korea Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 52. Australia Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 53. Australia Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 54. Australia Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 55. RoAPAC Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 56. RoAPAC Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 57. RoAPAC Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 58. Brazil Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 59. Brazil Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 60. Brazil Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 61. Mexico Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 62. Mexico Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 63. Mexico Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 64. RoLA Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 65. RoLA Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 66. RoLA Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 67. Saudi Arabia Blood Plasma DerivativesMarket estimates & forecasts, 2020-2030 (USD Million)
  • TABLE 68. South Africa Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 69. RoMEA Blood Plasma DerivativesMarket estimates & forecasts by segment 2020-2030 (USD Million)
  • TABLE 70. List of secondary sources, used in the study of global Blood Plasma DerivativesMarket
  • TABLE 71. List of primary sources, used in the study of global Blood Plasma DerivativesMarket
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Blood Plasma DerivativesMarket, research methodology
  • FIG 2. Global Blood Plasma DerivativesMarket, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Blood Plasma DerivativesMarket, key trends 2022
  • FIG 5. Global Blood Plasma DerivativesMarket, growth prospects 2023-2030
  • FIG 6. Global Blood Plasma DerivativesMarket, porters 5 force model
  • FIG 7. Global Blood Plasma DerivativesMarket, pest analysis
  • FIG 8. Global Blood Plasma DerivativesMarket, value chain analysis
  • FIG 9. Global Blood Plasma DerivativesMarket by segment, 2020 & 2030 (USD Million)
  • FIG 10. Global Blood Plasma DerivativesMarket by segment, 2020 & 2030 (USD Million)
  • FIG 11. Global Blood Plasma DerivativesMarket by segment, 2020 & 2030 (USD Million)
  • FIG 12. Global Blood Plasma DerivativesMarket by segment, 2020 & 2030 (USD Million)
  • FIG 13. Global Blood Plasma DerivativesMarket by segment, 2020 & 2030 (USD Million)
  • FIG 14. Global Blood Plasma DerivativesMarket, regional snapshot 2020 & 2030
  • FIG 15. North America Blood Plasma DerivativesMarket 2020 & 2030 (USD Million)
  • FIG 16. Europe Blood Plasma DerivativesMarket 2020 & 2030 (USD Million)
  • FIG 17. Asia pacific Blood Plasma DerivativesMarket 2020 & 2030 (USD Million)
  • FIG 18. Latin America Blood Plasma DerivativesMarket 2020 & 2030 (USD Million)
  • FIG 19. Middle East & Africa Blood Plasma DerivativesMarket 2020 & 2030 (USD Million)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Blood Plasma Derivatives Market is valued at approximately USD 43650.9 million in 2022 and is anticipated to grow with a healthy growth rate of more than 9.4% over the forecast period 2023-2030. The blood plasma derivatives market refers to the segment of the pharmaceutical industry that involves the collection, processing, and commercialization of therapeutic products derived from human blood plasma. These derivatives are obtained through a complex manufacturing process that includes fractionation, purification, and sterilization to isolate and extract specific proteins, antibodies, and other bioactive substances found in blood plasma. These products are used for various therapeutic purposes, including treating immune disorders, coagulation disorders, and certain genetic diseases. The blood plasma derivatives market is being driven by factors such as the increasing geriatric population that are more susceptible to developing infectious diseases and the Increasing prevalence of chronic diseases.

Blood plasma derivatives play a crucial role in the treatment of various medical conditions and provide therapeutic options for patients with immune deficiencies, coagulation disorders, and other diseases. According to the International Diabetes Federation (IDF), diabetes can afflict 537 million adults globally in 2021, with one in ten experiencing other diabetes. Furthermore, geriatric, and obese populations are predisposed to chronic diseases. According to the World Bank Group, the world old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050.Thus, the growing prevalence of chronic disease and the growing aging population fueling the growth of the market. In addition, increasing awareness & diagnosis of rare diseases and technological advancements in plasma fractionation. However, strict regulatory compliances may hinder the growth of the market throughout the forecast period of 2023-2030.

The key regions considered for the Global Blood Plasma Derivatives Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the well-developed healthcare infrastructure, including hospitals, clinics, and diagnostic centers. These facilities have advanced capabilities for blood plasma collection, processing, and manufacturing of derivatives, leading to a robust market for plasma-based products. North America is also considered the fastest growing region during the forecasted period due to the high demand for plasma-derived products and reimbursement systems.

Major market player included in this report are:

  • Baxter International Inc.
  • Bayer AG
  • CSL Limited
  • Fusion Health Care Pvt. Ltd.
  • Grifols S.A.
  • Kedrion S.p.A.
  • LFB S.A.
  • Octapharma AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Recent Developments in the Market:

  • In March 2020, Grifols collaborates with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease. Grifols will volunteer its expertise and resources in the areas of plasma collection using its network of FDA-approved plasma donor centers; test and qualify donors in conjunction with other health agencies; process plasma into hyperimmune globulin in its purpose-built facility in Clayton, North Carolina, for the isolated processing of immune globulins to treat emerging infectious diseases.

Global Blood Plasma Derivatives Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: , Type, Application, End User, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • Albumin
  • Factor VIII
  • Factor IX
  • Immunoglobulin
  • Hyperimmune Globulin
  • Others

By Application:

  • Hemophilia
  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Von Willebrand'S Disease
  • Other Application

By End User:

  • Hospitals
  • Clinics
  • Others End User

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
    • 1.2.1. Blood Plasma Derivatives Market, by Region, 2020-2030 (USD Million)
    • 1.2.2. Blood Plasma Derivatives Market, by Type, 2020-2030 (USD Million)
    • 1.2.3. Blood Plasma Derivatives Market, by Application, 2020-2030 (USD Million)
    • 1.2.4. Blood Plasma Derivatives Market, by End User, 2020-2030 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Blood Plasma Derivatives Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Blood Plasma Derivatives Market Dynamics

  • 3.1. Blood Plasma DerivativesMarket Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of chronic diseases
      • 3.1.1.2. Growing Geriatric Population
    • 3.1.2. Market Challenges
      • 3.1.2.1. Strict regulatory compliances
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing awareness & diagnosis of rare diseases
      • 3.1.3.2. Technological advancements in plasma fractionation

Chapter 4. Global Blood Plasma DerivativesMarket Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Blood Plasma DerivativesMarket, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Blood Plasma DerivativesMarket by Type, Performance - Potential Analysis
  • 5.3. Global Blood Plasma DerivativesMarket Estimates & Forecasts by Type 2020-2030 (USD Million)
  • 5.4. Blood Plasma DerivativesMarket, Sub Segment Analysis
    • 5.4.1. Albumin
    • 5.4.2. Factor VIII
    • 5.4.3. Factor IX
    • 5.4.4. Immunoglobulin
    • 5.4.5. Hyperimmune Globulin
    • 5.4.6. Others

Chapter 6. Global Blood Plasma DerivativesMarket, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Blood Plasma DerivativesMarket by Application, Performance - Potential Analysis
  • 6.3. Global Blood Plasma DerivativesMarket Estimates & Forecasts by Application 2020-2030 (USD Million)
  • 6.4. Blood Plasma DerivativesMarket, Sub Segment Analysis
    • 6.4.1. Hemophilia
    • 6.4.2. Hypogammaglobulinemia
    • 6.4.3. Immunodeficiency Diseases
    • 6.4.4. Von Willebrand'S Disease
    • 6.4.5. Other Application

Chapter 7. Global Blood Plasma DerivativesMarket, by End User

  • 7.1. Market Snapshot
  • 7.2. Global Blood Plasma DerivativesMarket by End User, Performance - Potential Analysis
  • 7.3. Global Blood Plasma DerivativesMarket Estimates & Forecasts by End User 2020-2030 (USD Million)
  • 7.4. Blood Plasma DerivativesMarket, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Clinics
    • 7.4.3. Others End User

Chapter 8. Global Blood Plasma DerivativesMarket, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Blood Plasma DerivativesMarket, Regional Market Snapshot
  • 8.4. North America Blood Plasma DerivativesMarket
    • 8.4.1. U.S. Blood Plasma DerivativesMarket
      • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Blood Plasma DerivativesMarket
  • 8.5. Europe Blood Plasma DerivativesMarket Snapshot
    • 8.5.1. U.K. Blood Plasma DerivativesMarket
    • 8.5.2. Germany Blood Plasma DerivativesMarket
    • 8.5.3. France Blood Plasma DerivativesMarket
    • 8.5.4. Spain Blood Plasma DerivativesMarket
    • 8.5.5. Italy Blood Plasma DerivativesMarket
    • 8.5.6. Rest of Europe Blood Plasma DerivativesMarket
  • 8.6. Asia-Pacific Blood Plasma DerivativesMarket Snapshot
    • 8.6.1. China Blood Plasma DerivativesMarket
    • 8.6.2. India Blood Plasma DerivativesMarket
    • 8.6.3. Japan Blood Plasma DerivativesMarket
    • 8.6.4. Australia Blood Plasma DerivativesMarket
    • 8.6.5. South Korea Blood Plasma DerivativesMarket
    • 8.6.6. Rest of Asia Pacific Blood Plasma DerivativesMarket
  • 8.7. Latin America Blood Plasma DerivativesMarket Snapshot
    • 8.7.1. Brazil Blood Plasma DerivativesMarket
    • 8.7.2. Mexico Blood Plasma DerivativesMarket
  • 8.8. Middle East & Africa Blood Plasma DerivativesMarket
    • 8.8.1. Saudi Arabia Blood Plasma DerivativesMarket
    • 8.8.2. South Africa Blood Plasma DerivativesMarket
    • 8.8.3. Rest of Middle East & Africa Blood Plasma DerivativesMarket

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Baxter International Inc.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Bayer AG
    • 9.3.3. CSL Limited
    • 9.3.4. Fusion Health Care Pvt. Ltd.
    • 9.3.5. Grifols S.A.
    • 9.3.6. Kedrion S.p.A.
    • 9.3.7. LFB S.A.
    • 9.3.8. Octapharma AG
    • 9.3.9. Sanofi S.A.
    • 9.3.10. Takeda Pharmaceutical Company Limited

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption